Sudeep Pharma
Mainboard₹14,825 / 25 Shares
IPO Live Subscription Details
| Category | Subscription (Times) |
|---|---|
| Date | 25 Nov 2025, 05:57 PM |
| QIBs | 213.08 times |
| NII | 116.72 times |
| Retail | 15.65 times |
| Total | 93.71 times |
Sudeep Pharma IPO Details
The Sudeep Pharma IPO price band is set between ₹563-593 per equity share, with a face value of ₹1 per share. The issue is managed by MUFG Intime India Pvt Ltd, and the equity shares are proposed to be listed on the Mainboard.
The IPO date for subscription opens on 21 Nov, 2025 and closes on 25 Nov, 2025. Investors can check the allotment status on 26 Nov, 2025, while the listing date is tentatively scheduled for 28 Nov, 2025.
The total issue size is 1,50,92,750 shares, aggregating up to ₹895 crore. Stay tuned for the latest Sudeep Pharma IPO review and GMP updates.
Sudeep Pharma IPO Review, Rating & Analysis
Sudeep Pharma IPO Review
NeutralSudeep Pharma IPO Rating
Sudeep Pharma IPO Highlights
IPO Date
Nov 21, 2025 - Nov 25, 2025
Listing Date
28 Nov, 2025
Face Value
₹1 Per Equity Share
Price Band
₹563-593 per equity share
Lot Size
25 Shares
Fresh Issue
Shares
Offer for Sale
-
Listing At
BSE, NSE
Sudeep Pharma IPO Lot Size
The minimum market lot for Sudeep Pharma IPO is 25 shares with an application amount of ₹14,825. Retail investors can apply for up to 13 lots. The table below details the minimum and maximum investment limits for Retail and HNI investors.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹1,92,725 |
| S-HNI (Min) | 14 | 350 | ₹2,07,550 |
| S-HNI (Max) | 67 | 1675 | ₹9,93,275 |
| B-HNI (Min) | 68 | 1700 | ₹10,08,100 |
Sudeep Pharma IPO Timeline
Issue Price
₹563-593 per equity shareFace Value
₹1 Per Equity ShareListing at Group
BSE, NSERegistrar
MUFG Intime India Pvt LtdLead Manager
ICICI Securities Ltd.IIFL Capital Services Ltd.Issue Size
1,50,92,750 shares(aggregating up to ₹895 crore)Sudeep Pharma IPO Reservation Details
| Investor Category | Shares Offered | % Shares |
|---|---|---|
| Anchor Investor Shares Offered | 4527823 | 30% |
| QIB Shares Offered | 3018553 | 20% |
| NII (HNI) Shares Offered | 2263912 | 15% |
| bNII > ₹10L | 1509275 | 10% |
| sNII < ₹10L | 754637 | 5% |
| Retail Shares Offered | 5282462 | 35% |
| Total Shares Offered | 15092750 | 100% |
Sudeep Pharma IPO Documents
Sudeep Pharma IPO Valuations
EPS Pre IPO
₹12.46/-EPS Post IPO
₹11.07/-PE Pre IPO
47.61PE Post IPO
53.55ROE
-ROCE
-Debt Equity
0.20RoNW
27.88%PAT Margin
27.63%Price to Book Value
12.93Promoters & Share Holding
Promoter(s) Name
- Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources Private Limited, and Bhayani Family Trust
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| 89.36% | 76.15% |
About Company
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.It has six manufacturing facilities that have a combined production capacity of 50,000 MT, manufacturing minerals such as calcium, iron, magnesium, zinc, potassium, and sodium.
The company supplies over 200 products to a wide customer base across the pharma, food, and nutrition sectors.The company has strong R&D capabilities comprising in-house labs and pilot-scale facilities for mineral salts and excipients.
Product Portfolio:
Pharmaceutical, Food and Nutrition Business
Specialty Ingredients Business
Triturates As of 31 December 2024, the company had 704 permanent employees.
Sudeep Pharma IPO Subscription Details
| As on | QIB | NII bNII sNII | Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 30,18,553 | 22,63,912
15,09,275
7,54,637
| 52,82,462 | 1,05,64,927 |
Day 121-11-25 05:00 PM | 0.09 x | 3.00
x
2.75 x
3.51 x
| 1.51 x | 1.42 x |
Day 224-11-25 05:00 PM | 0.13 x | 12.01
x
10.99 x
14.04 x
| 4.99 x | 5.11 x |
Day 325-11-25 05:00 PM | 213.08 x | 116.72
x
134.91 x
80.33 x
| 15.65 x | 93.71 x |
Retail:12.88x
BHNI:27.29x
SHNI:76.34x
Sudeep Pharma IPO - Issue Objectives & Utilisation of proceeds
| Objectives | Amount |
|---|---|
| Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I | ₹ 75.81 Cr |
| General corporate purposes | - |
Company Contact Details
Sudeep Pharma
129/1/A, GIDC Estate, Nandesari, Vadodara, Gujarat, 391340Registrar Contact Details
MUFG Intime India Private Limited (Link Intime)
Phone: +91-22-4918 6270
Email: sudeeppharma.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Frequently Asked Questions about Sudeep Pharma IPO
When will Sudeep Pharma IPO open for subscription?
The Sudeep Pharma IPO opens on 21 Nov, 2025 and closes on 25 Nov, 2025.
What is the investors portion for Sudeep Pharma IPO?
The investors' portion for QIB is 213.08 x, NII is 134.91 x, and Retail is 15.65 x.
How to apply for Sudeep Pharma IPO?
You can apply for Sudeep Pharma IPO via ASBA online through your bank account. You can also apply via UPI through stock brokers like Zerodha, Upstox, or Paytm Money.
What is the issue size of Sudeep Pharma IPO?
The issue size of Sudeep Pharma IPO is approx ₹1,50,92,750 shares(aggregating up to ₹895 crore) crores.
What is the price band of Sudeep Pharma IPO?
The price band for Sudeep Pharma IPO is ₹563 to ₹593 per equity share.
What is the lot size of Sudeep Pharma IPO?
The minimum bid (lot size) for Sudeep Pharma IPO is 25 shares with an investment of approx ₹14,825 .
What is the allotment date of Sudeep Pharma IPO?
The allotment date for Sudeep Pharma IPO is 26 Nov, 2025.
What is the listing date of Sudeep Pharma IPO?
The listing date for Sudeep Pharma IPO is expected to be 28 Nov, 2025.
What is the GMP of Sudeep Pharma IPO?
The latest Grey Market Premium (GMP) for Sudeep Pharma IPO is being updated regularly on IPOROCK.
Parth D.
Founder & Lead Analyst
Parth D. is a software engineer and financial analyst who brings a quantitative edge to IPO tracking. With deep expertise in algorithmic trading and financial tool development, he builds the technology that powers IPORock's real-time data engines. He has been tracking the Indian market since 2018.